Humanized Antibody Binding Amyloid Beta
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyloidosis, particularly Alzheimer's Disease and age-related macular degeneration, are inadequate in preventing or reversing the progression of amyloid plaque formation and associated complications, with existing medications having modest effects and significant side effects.
Innovation Solution
Development of humanized antibodies that specifically recognize and bind to various forms of β-amyloid proteins, including monomers, oligomers, and fibrils, inhibiting aggregation and inducing disaggregation of amyloid plaques, thereby addressing the underlying pathology of amyloidosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat amyloidosis, then treatment is provided, but the effects are modest and significant side effects occur
Solution Approach 1:
The patent changes the molecular structure parameters of the treatment agent by humanizing the antibody (modifying amino acid sequences in the variable regions) to reduce immunogenicity while maintaining binding affinity to amyloid-beta, thereby reducing side effects while preserving treatment effectiveness
Solution Approach 2:
The patent creates a humanized copy of the mouse monoclonal antibody 266 by transferring the antigen-binding CDR regions into a human antibody framework, producing a humanized antibody that retains the original's ability to bind amyloid-beta while having improved compatibility with human physiology
2Reliability
If antibodies are developed to bind to various forms of β-amyloid proteins, then aggregation inhibition and disaggregation are achieved, but the complexity of the antibody design increases
Solution Approach 1:
The patent designs a universal humanized antibody that can bind to multiple forms of amyloid-beta proteins (monomers, oligomers, and fibrils) through a single antibody structure, achieving multi-functionality without requiring multiple different antibodies
Solution Approach 2:
The patent modifies only the specific CDR regions of the antibody to maintain high binding affinity for amyloid-beta while keeping the rest of the antibody structure human-derived and relatively simple, applying changes locally rather than throughout the entire molecule
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.